IN8BIO Inc. has released a corporate presentation detailing advances in its pipeline focused on gamma-delta (γδ) T cell therapies. The update highlights ongoing clinical and preclinical programs, including the DeltEx platform for acute myeloid leukemia (AML) and glioblastoma (GBM), with ongoing patient dosing and upcoming clinical updates projected for late 2026. The presentation also outlines research into non-signaling CAR-T cells, induced pluripotent stem cell (iPSC)-derived T cells, and T cell engagers for potential applications in oncology and autoimmune diseases. Additional data on completed trials and plans for regulatory engagement with the FDA are provided. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.